Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Signatures of Cutaneous Dupilumab Response
NCT05858619Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Feb 2023
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by University of California, San Francisco. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05858619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858619.